CompletedNCT02006628
A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Czeladź and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: February 25, 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 88
- Sponsor
- Jazz Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom, Poland, Romania
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02006628
- Official title
Show the full official title
A Double-blind, Randomised, Placebo-controlled, Parallel Group Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
Get this study by email
Recruitment & locations
CompletedCzeladź, Poland · Gdansk, Poland · Kielce, Poland
10 more locations
- Lublin, Poland
- Tychy, Poland
- Wroclaw, Poland
- Bucharest, Romania
- Sibiu, Romania
- Targoviste, Romania
- Târgu Mureş, Romania
- Chertsey, United Kingdom
- Coventry, United Kingdom
- London, United Kingdom
Questions about this study
Who is behind this study?
The study sponsor is Jazz Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Placebo and GWP42003.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit meRelated studies
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...